Effect and safety evaluation of tirofiban on medial dangerous acute coronary syndrome
AIM: To explore the efficacy and safety of quadruple therapy of aspirin, clopidogrel, low molecular weight heparin (LMWH) and tirofiban hydrochloride in the treatment of patients with medial dangerous non-ST-segment elevation acute coronary syndrome(NSTE-ACS). METHODS: Totally, 117 hospitalized patients with medial dangerous NSTE-ACS were included in the study, 57 of whom were assigned to observation group and 60 of whom to control group. In addition to aspirin, elopidogrel and hypodermically injected LMWH given to all the patients in both groups, tirofiban was given intravenously in observation group. RESULTS: Significant decrease in all-cause death, occurrence of refractory angina pectoris and within-d-day emergency PCI was observed in observation group compared with that in control group (P＜0.05), but no marked difference was found in the recurfence of myocardial infarction. More mild hemorrhage occurred in observation group compared with that in control group (P＜ 0.05). CONCLUSION: Quadruple therapy is safe and effective in the treatment of medial dangerous non-ST-segment elevation ACS.
NETL
NSTL
万方数据
维普
